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Hematotoxicity and its complication are the prominent limiting factors for rational treatment of malignancies. Granulocyte colony-
stimulating factor (G-CSF) is used to increase granulocyte production. It has been shown previously that enterosorption causes prominent 
myeloprotective activity also. Still, no trial was performed to combine both of them. Aim: To study the influence of combination of en-
terosorption and pharmaceutical analogue of naturally occurring G-CSF (filgrastim) on bone marrow protection and the growth 
of grafted tumor in a case of injection of melphalan (Mel). Materials and Methods: Mel injections were used for promotion of bone 
marrow suppression in rats. Carbon granulated enterosorbent C2 (IEPOR) was used for providing of enteral sorption detoxifying thera-
py. Filgrastim was used to increase white blood cells (WBC) count. Results: The simultaneous usage of enterosorption and filgrastim had 
maximum effectiveness for restoring of all types of blood cells. WBC count was higher by 138.3% compared with the Mel group. The in-
crease of platelets count by 98.5% was also observed. In the group (Mel + C2 + filgrastim) the absolute neutrophils count was twofold 
higher, in comparison with rats of Mel group. Conclusion: Simultaneous admi nistration of G-CSF-analogue and carbonic enterosorbent 
C2 is a perspective approach for bone marrow protection, when the cytostatic drug melphalan is used. Such combination demonstrates 
prominent positive impact on restoring of all types of blood cells and had no influence on the antitumor efficacy.
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Uncontrolled cell division is one of the features of can-
cer cells. The common side effects of anti-cancer drugs, 
which have no selective activity against tumors, include 
damaging of all highly proliferative cells. The critical tis-
sues and organs are the bone marrow, mucosa of gas-
trointestinal tract, ovaries and testis in this case.
Dose-dense and dose-intense chemotherapy may 
result in the suppression of activity of proliferating hema-
topoietic precursor cells, leading to deprivation of blood 
cells and incidence of life threatening hemorrhage and 
infections [1]. Hematotoxicity and its complication similar 
to febrile neutropenia and sepsis are the prominent limiting 
factors for successful treatment of malignancies. It often 
results in lengthy treatment delays and dose reductions, 
which have been shown to compromise the treatment.
The endogenous intoxication syndrome can deve-
lop in oncological patients as well. The main factors are: 
“tumor disposition”; tumor-dependent compression 
or tumor invasion; destruction of neoplastic tissues due 
to aggressive treatment; surgical trauma; hemorrhage; 
sepsis; prominent oxidative stress, etc. [2–4]. All these 
features decrease the activity of detoxifying systems 
of organism, i.e. elimination of waste products, inhibit 
the liver and kidney functions and disrupt the important 
biochemical process.
Over the past years, a new class of drugs has be-
come available to boost marrow function — the recom-
binant hematopoietic growth factors. Erythropoietin 
is used to increase red blood cells (RBC) production; 
granulocyte colony-stimulating factor (G-CSF) and 
granulocyte-macrophage colony-stimulating fac-
tor — to increase granulocyte production; and inter-
leukin-11 is administered to increase platelet count [1].
Finally, studies have shown that filgrastim, lenogras-
tim and pegfilgrastim (G-CSF analogues) have clinical ef-
ficacy. The use of any of these agents was recommended 
to prevent febrile neutropenia and related complications. 
Despite the fact that G-CSF reduces the neutropenia 
duration for 1–2 days, it has no influence on such clini-
cal parameters like fever severity, intensity of antibiotics 
therapy and lethality indices. However, additional G-CSF-
therapy increases the cost of treatment notably [5–7].
Enteral sorption detoxifying therapy is used widely 
today to decrease the systemic signs of acute or chronic 
intoxication and oxidative stress in case of renal failure, 
hepatic insufficiency, burn toxicosis, and acute enteric 
infections [8–13], as well as complications of chemo- 
and radiotherapy of cancer [3, 12, 14–16]. It was shown 
previously that enterosorption causes prominent my-
eloprotective activity in case of applying of therapeutic 
doses of alkylating agent melphalan (Mel) and demon-
strates some other positive effects [17].
Still, to the best of our knowledge, no trial was per-
formed to combine this technique with myeloprotective 
cytokines. At the same time, it is known, that some 
metabolic corrections by antioxidants and vitamins can 
promote the tumor growth [18]. So, it is very important 
to understand what influence the different additive 
medicines might have on malignancy progress.
The aim of our investigation is to study the ef-
ficacy of combination of enterosorption and G-CSF 
analogue to protect the bone marrow in case of injection 
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of high dose of alkylating bifunctional cytostatic drug 
of the bischloroethylamine type — Mel, which is widely 
used in the palliative treatment of patients with multiple 
myeloma, advanced ovarian cancer, etc. [19].
The influence of combined administration of entero-
sorption and G-CSF analogue filgrastim on the growth 
of grafted Guerin’s carcinoma in rats is studied as well.
MATERIALS AND METHODS
Melphalan (Mel) was used for promotion of bone 
marrow suppression in rats. It is an alkylating anti-can-
cer drug Mel, also known as L-phenylalanine mustard 
(L-PAM), phenylalanine mustard, or L-sarcolysin.
Carbon granulated enterosorbent C2 (R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology, NAS of Ukraine — IEPOR) was used for 
detoxifying therapy by enteral sorption therapy. Parame-
ters of carbonic enterosorbent C2 were the following: 
a bulk density γ = 0.18 g/cm3, a diameter of granules 
0.15–0.25 mm, the BET pore surface — 2162 m2/g.
Filgrastim was used to increase white blood cells 
(WBC) count. It is a G-CSF analogue which used to stimu-
late the proliferation and differentiation of granulocytes, 
which is produced by recombinant DNA technology.
Animals and experiment design. The first part 
of experiment was carried out on 65 healthy male inbred 
albino Wistar rats weighing 200 ± 20 g from the IEPOR 
animal facility. All procedures were performed according 
to the rules and requirements of European Convention 
for the Protection of Vertebrate Animals Used for Experi-
mental and Other Scientific Purposes and a local Ethic 
Committee of IEPOR. Animals were randomly distributed 
into 5 groups: group 1 — intact rats (n = 25); group 2 — 
rats treated with Mel (n = 10, control group); group 3 — 
animals treated with Mel and carbonic enterosorbent 
C2 (Mel + C2, n = 10); group 4 — rats treated with Mel 
and filgrastim (Mel + filgrastim, n = 10); and group 5 — 
rats treated with Mel and both carbonic enterosorbent 
C2 and filgrastim (Mel + C2 + filgrastim, n=10).
Experiment was carried out to study the influence 
of administration of enterosorption and G-CSF on the dy-
namics of tumor growth. For this purpose, we used 
35 female inbred albino Wistar rats with grafted tumors. 
Suspension of Guerin’s carcinoma tumor tissues (23%, 
0.4 ml) was applied subcutaneously to the back of ani-
mals. All rats were randomly distributed into 5 groups 
(n = 7 in each group) after formation of tumor in 8 days: 
group 1 — Guerin’s carcinoma-bearing rats (tumor con-
trol); group 2 — Guerin’s carcinoma-bearing rats treated 
with Mel (tumor + Mel); group 3 — treated with Mel and 
C2 (tumor + Mel + C2); group 4 — treated with Mel and 
filgrastim (tumor + Mel + filgrastim) and group 5 — with 
Mel, C2 and filgrastim (tumor+ Mel + C2 + filgrastim).
The dynamics of tumor growth in all groups was cal-
culated by the formula:
V = a · b · c · π/6,
where V — the volume of tumor (сm3); a, b, c — or-
thogonal sizes of tumor (сm).
Mel has been injected intravenously as a single treat-
ment in tail vein 4.0 mg/kg of body weight. The dose 
of alkylating cytostatic was 5.5 mg/kg for the rats with 
grafted Guerin’s carcinoma. A suspension of carbonic 
enterosorbent (C2 dosage of 5 ml/1 kg of animals body 
weight, 900 mg of dry mass of enterosorbent) in ap-
propriate quantity of distilled water was introduced via 
the tube into rat stomach during 3 days before the day 
of Mel injection and during 7 days after injection (1 time 
per 1 day). The filgrastim was injected once a day 
 starting from the next day after Mel applying during 
4 days in dose 50 mcg/kg. Rats of Mel group and intact 
group were given equivalent quantity of distilled water. 
Animals of intact group received intravenously equal 
quantities of saline instead of Mel.
The rats were weighted and blood was taken from 
the heart under Ketamine hydrochloride general anesthe-
sia on the 8th day after Mel injection. We used automatic 
hematology analyzer BC-3000Plus Mindray for evaluation 
of complete blood cell count. Peripheral blood smears 
were made as well. Panoptic method of Pappenheim was 
used for the staining of cytological smears [20]. 
Statistical analysis. Since data were not normally 
distributed in all groups (Shapiro — Wilk Normality Test), 
non-parametric tests (Mann — Whitney U-test and 
one-way ANOVA test) were performed for analysis of all 
data (significant at pb 0.05). The data were expressed 
as the mean ± standard error of the mean (M ± m). All 
statistical calculations were performed on the separate 
data from each individual with using Origin 7.5 software 
(OriginLab Corporation, USA).
RESULTS
It was observed that Mel at a dose of the 4 mg/kg in-
fluenced negatively on blood cells. For example, WBC 
count decreased by 75.6%, while platelets count — 
by 59.9% compared with intact rats (Table 1). Decrease 
of red blood indices was not so prominent: erythrocyte 
count was lower by 10.3% and there were no changes 
of hemoglobin level. The enterosorbent C2 pro-
moted the increase of WBC count by 43.8%, as well 
as the tendency of platelets concentration increase 
was noted too. Filgrastim caused the significant rising 
of WBC count by 57.0%. The most effective results 
were observed in case of combined use (C2 and 
filgrastim): amount of WBC was higher by 138.3% 
compared with the Mel group; and higher (by 65.8%) 
compared with Mel + C2 group. The leukocytes count 
was higher by 51.7% in rats which were administered 
sorbent C2 and filgrastim compared with usage of fil-
grastim alone. Interestingly, we observed the increase 
of platelets by 98.5% in case of combined treatment 
of enterosorbent C2 and filgrastim. This index is higher 
by 126.4% compared with Mel + filgrastim group.
As one can see in leucocytes formula (Table 2), Mel 
at dose of 4 mg·kg-1 caused the 89.0% increase of neu-
trophils, while the percent of lymphocytes decreased 
by 46.1%, and amount of monocytes was 3 times-fold 
higher (increased by 200.5%). The usage of enteral 
sorption therapy and filgrastim had no influence on per-
centage of leukocytes formula. Simultaneously, it was 
observed that absolute neutrophils count decreased 
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by 53.8% and absolute lymphocytes count — by 86.8% 
(Table 3).
The combined treatment with carbonic enterosor-
bent C2 and filgrastim had maximum effectiveness for 
restoring of all types of WBC. For example, in group 
Mel + C2 + filgrastim the neutrophils absolute count 
was higher by 196.1%, lymphocytes — by 101.0% 
compared with Mel group. Neutrophils absolute count 
in mentioned group was higher by 135.6% compared 
with usage of enterosorbent alone and higher by 77.3% 
compared with usage of filgrastim alone.
Analysis of Guerin’s carcinoma growth in the groups 
of rats with grafted tumors has shown that administra-
tion of carbonic enterosorbent C2 or filgrastim, or its 
combination, had no effect on the antitumor efficacy 
of Mel. On the 13th day after tumor transplantation, 
the average sizes of tumor volume were the same 
in Guerin’s carcinoma-bearing rats, which have got 
the enterosorbent and/or filgrastim besides the Mel, 
and in rats treated with Mel alone (Table 4).
Table 4. The dynamics of Guerin’s carcinoma growth (volume, cm3)
Group
Days after transplantation of Guerin’s 
carcinoma
7 10 13 17
Tumor control (n = 7) 0.9 ± 0.1 3.7 ± 0.2 7.7 ± 0.2 11.3 ± 0.2
Tumor + Mel (n = 7) 0.9 ± 0.1 3.8 ± 0.3 5.8 ± 0.2* 6.6 ± 0.2*
Tumor + Mel+ filgrastim (n = 7) 0.8 ± 0.2 3.7 ± 0.2 5.8 ± 0.3* 6.4 ± 0.3*
Tumor + Mel + C2 (n = 7) 1.0 ± 0.1 3.5 ± 0.2 5.7 ± 0.3* 6.1 ± 0.2*
Tumor + Mel + filgrastim + 
C2 (n = 7) 1.0 ± 0.1 3.8 ± 0.3 5.7 ± 0.3* 6.0 ± 0.4*
Note: * the significance р < 0.05 comparatively with the tumor control. 
The slight tendency to enhancement of Mel inhibiting 
action in case of simultaneous usage of enteral detoxifying 
sorption therapy and filgrastim was observed on day 17.
DISCUSSION
Myelosuppression is a common and expected side 
effect of antitumor treatment, especially using alkylating 
agents. Because of it, patients may experience ane-
mia, neutropenia, and thrombocytopenia. Depending 
on their severity, these side effects can have a negative 
impact on patient’s medical treatment and quality of life 
leading to therapy interruption or reduction and causing 
life-threatening complications. Neutropenia, including 
febrile neutropenia, can result in life-threatening infec-
tions. Overall mortality rates due to febrile neutropenia 
are about 5% in patients with solid tumors and as high 
as 11% in some hematological malignancies. Prog-
nosis is the worst in patients with proven bacteremia, 
with mortality rates of 18% in Gram-negative and 5% 
in Gram-positive bacteremia [21, 22].
Today, G-CSF is being used prophylactically to sup-
port the dose-dense and dose-intense chemotherapy 
regimens, in spite of the insufficient data to assess 
the impact of G-CSF on disease-free and overall survi-
val [23] and side effects of such treatment [24]. Results 
of this study show the potent myeloprotective effect 
of G-CSF as filgrastim caused the significant rising 
of WBC (by 57.0%). At the same time, there is no effect 
on other types of blood cells in case of its administra-
tion alone. Filgrastim did not show a potent impact 
on restoration of antioxidant-prooxidant balance also.
In case of enteral sorption detoxifying therapy, es-
pecially in combination with the filgrastim, one can see 
the 2.3-fold increase of platelets count, compared with 
Mel + filgrastim group. It is well known that endogenic 
intoxication is prominent negative factor in patients with 
malignant tumors [25]. Enterosorption demonstrates 
Table 1. Hematological indices in case of Mel injection at dose 4 mg·kg-1 and its correction by carbonic enterosorbent C2 and filgrastim (M ± m)
Parameters
Groups
Intact rats
(n = 25)
Mel
(n = 10)
Mel + C2
(n = 10)
Mel + filgrastim
(n = 10)
Mel + C2 + filgrastim
(n = 10)
Leukocytes, ×109/l 5.24 ± 0.29 1.28 ± 0.15* 1.84 ± 0.17** 2.01 ± 0.16# 3.05 ± 0.28**, #, ##
Erythrocytes, ×1012/l 7.34 ± 0.12 6.58 ± 0.17* 6.66 ± 0.20 6.85 ± 0.19 6.80 ± 0.15
Hemoglobin, g/l 134.32 ± 1.69 115.90 ± 3.46 122.10 ± 2.24 121.60 ± 2.84 122.0 ± 2.97
Platelets, ×109/l 634.84 ± 22.97 254.60 ± 45.59* 328.10 ± 65.65 223.20 ± 40.45 505.40 ± 70.68**, ##
Notes: significance р < 0.05 comparatively with: *intact rats; **Mel treatment; #Mel + C2 group treatment; ##Mel + filgrastim treatment.
Table 2. Leukocytes formula in case of Mel injection at dose 4 mg·kg−1 and its correction by carbonic enterosorbent C2 and filgrastim (M ± m, n = 10)
Parameters GroupsIntact rats Mel Mel + C2 Mel + filgrastim Mel + C2 + filgrastim
Promyelocytes, % − − − − −
Myelocytes, % − − − − −
Metamyelocytes, % − − − 0.40 ± 0.27 0.22 ± 0.22
Neutrophils, % 25.90 ± 1.83 49.0 ± 3.76* 42.83 ± 3.19 51.30 ± 5.61 60.89 ± 5.19
Eosinophils, % 1.0 ± 0.45 − − − −
Basophils, % − − − 0.10 ± 0.10 −
Lymphocytes, % 68.4 ± 3.10 36.88 ± 4.42* 42.34 ± 3.07 36.0 ± 4.71 31.11 ± 4.05
Monocytes, % 4.70 ± 0.97 14.12 ± 2.12* 14.83 ± 2.61 12.20 ± 2.45 7.78 ± 2.09
Notes: significance р < 0.05 comparatively with: *intact rats; **Mel treatment; #Mel + C2 treatment; ##Mel + filgrastim treatment.
Table 3. Absolute blood cells count in case of Mel injection in dose 4 mg·kg-1 and its correction by carbonic enterosorbent C2 and filgrastim (M ± m, n = 10)
Parameters GroupsIntact rats Mel Mel + C2 Mel + filgrastim Mel + C2 + filgrastim
Promyelocytes, ×109/l − − − − −
Myelocytes, % − − − − −
Metamyelocytes, % − − − 0.01 ± 0.01 0.01 ± 0.01
Neutrophils, ×109/l 1.37 ± 0.09 0.63 ± 0.05* 0.79 ± 0.06 1.05 ± 0.12** 1.86 ± 0.16**, #, ##
Eosinophils, ×109/l 0.05 ± 0.02 − − − −
Basophils, ×109/l − − − − −
Lymphocytes, ×109/l 3.58 ± 0.16 0.47 ± 0.06* 0.78 ± 0.06** 0.71 ± 0.10 0.94 ± 0.12**
Monocytes, ×109/l 0.24 ± 0.05 0.18 ± 0.03 0.27 ± 0.05 0.24 ± 0.05 0.24 ± 0.06
Notes: significance р <0.05 comparatively with: *intact rats; **Mel group; #Mel + C2 group; ##Mel + filgrastim group.
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the proved systemic effects in such cases, diminishing 
the disruption of metabolism [3, 11, 26].
The overall positive effect of simultaneous admini-
stration of enterosorption and G-CSF could be explained 
by their different effects on human organism. The hemato-
poietic growth factor stimulates the bone marrow directly, 
while there are systemic positive effects of adsorptive 
therapy, such as the removal of toxic substances, some in-
termediate metabolites, attenuation of “metabolic chaos” 
and oxidative stress. These factors improve the detoxi fying 
function of body itself and, possibly, binding of some sub-
stances, which can limit the restoration of bone marrow 
function. Enteral sorption therapy and G-CSF do not cause 
any negative effect on the antitumor activity of cytostatic 
drug also, as was shown by results of our experiment.
CONCLUSIONS
Simultaneous administration of filgrastim, an ana-
logue of G-CSF and carbonic enterosorbent C2 is a pro-
spective approach for bone marrow protection in case 
of usage of cytostatic drug Mel.
In case of the cytostatic bone marrow suppression, 
simultaneous administration of the hematopoietic 
growth factor (G-CSF, filgrastim) and carbonic entero-
sorbent C2 demonstrated significant myeloprotective 
effect and synergy in comparison with single effects 
of each agent alone. We observed restoration of all 
types of blood cells and more pronounced increase 
of absolute neutrophils and lymphocytes counts. Inte-
restingly, platelets count increased as well.
Filgrastim used in combination with the carbonic 
enterosorbent C2 and its alone administration had 
no effect on the antitumor efficacy of Mel.
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